Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,593.65 +56.35 (+0.21%) CMC Crypto 200
565.87 -2.18 (-0.38%)
Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 15.93 |
| Open | 15.86 |
| Bid | 15.60 x 3200 |
| Ask | 15.95 x 4000 |
| Day's range | 15.81 - 15.91 |
| 52-week range | 12.28 - 17.15 |
| Volume | |
| Avg. volume | 2,131,291 |
| Market cap | 49.518B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 24.37 |
| EPS (TTM) | 0.65 |
| Earnings date | N/A |
| Forward dividend & yield | 0.66 (4.14%) |
| Ex-dividend date | 29 Sept 2022 |
| 1y target est | 18.75 |
Business WireTakeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
OSAKA, Japan & CAMBRIDGE, Mass., September 20, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for TAK-721 (budesonide oral suspension) which is being investigated for the short-term treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease that can cause damage to the esophagus.1 The resubmission is intended to address previous FDA feedback to the Company’s ori
Business WireTakeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
OSAKA, Japan & CAMBRIDGE, Mass., September 13, 2023--Takeda (TSE:4502/NYSE:TAK) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries. The new partnerships bring its total contributions to JPY 24.2 billion (Approx. USD 167.5 million) across 29 long-term partnerships. Takeda’s workforce is an integral part of the annual decision-making process as over 24,500 purpose-le
Business WireTakeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
OSAKA, Japan & CAMBRIDGE, Mass., September 13, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO® (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with ENTYVIO intravenous (IV). An application for the SC administration of ENTYVIO for the tre
